APA (7th ed.) Citation

J, H., AG, B., CS, R., JV, B., & LK, S. (2025). Type I error control and interim monitoring for co-primary hypotheses involving a subgroup in the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) trial. Contemporary clinical trials communications, 49, 101592. https://doi.org/10.1016/j.conctc.2025.101592

Chicago Style (17th ed.) Citation

J, Hu, Babiker AG, Reilly CS, Baker JV, and Siegel LK. "Type I Error Control and Interim Monitoring for Co-primary Hypotheses Involving a Subgroup in the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) Trial." Contemporary Clinical Trials Communications 49 (2025): 101592. https://doi.org/10.1016/j.conctc.2025.101592.

MLA (9th ed.) Citation

J, Hu, et al. "Type I Error Control and Interim Monitoring for Co-primary Hypotheses Involving a Subgroup in the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) Trial." Contemporary Clinical Trials Communications, vol. 49, 2025, p. 101592, https://doi.org/10.1016/j.conctc.2025.101592.